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Comparing spot-scanning
proton therapy single-field
optimization plans with
volumetric modulated arc
therapy plans indicated that
single-field optimization can
achieve significant sparing of
normal tissue for mid-
esophageal cancer compared
with volumetric modulated
arc therapy. However, the
boost volume dose coverage
in the simultaneous inte-
grated boost proton plans
appears less robust to setup
errors. Robust optimization
to ensure adequate target
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http://dx.doi.org/10.1016/j.ijrobp.2016.01.044Purpose: Planning studies to compare x-ray and proton techniques and to select the
most suitable technique for each patient have been hampered by the nonequivalence
of several aspects of treatment planning and delivery. A fair comparison should
compare similarly advanced delivery techniques from current clinical practice and also
assess the robustness of each technique. The present study therefore compared volu-
metric modulated arc therapy (VMAT) and single-field optimization (SFO) spot scan-
ning proton therapy plans created using a simultaneous integrated boost (SIB) for dose
escalation in midesophageal cancer and analyzed the effect of setup and range uncer-
tainties on these plans.
Methods and Materials: For 21 patients, SIB plans with a physical dose prescription of
2Gy or 2.5Gy/fraction in 25 fractions to planning target volume (PTV)50Gy or PTV62.5Gy
(primary tumor with 0.5 cm margins) were created and evaluated for robustness to
random setup errors and proton range errors. Doseevolume metrics were compared
for the optimal and uncertainty plans, with P<.05 (Wilcoxon) considered significant.
Results: SFO reduced themean lung dose by 51.4% (range 35.1%-76.1%) and themean
heart dose by 40.9% (range 15.0%-57.4%) compared with VMAT. Proton plan robust-
ness to a 3.5% range error was acceptable. For all patients, the clinical target volume
D98 was 95.0% to 100.4% of the prescribed dose and gross tumor volume (GTV) D98
was 98.8% to 101%. Setup error robustness was patient anatomy dependent, and the po-
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might be beneficial.clinical target volume D98 was lower by 0.6% to 7.8% of the prescribed dose, and the
GTV D98 was lower by 0.3% to 2.2% of the prescribed GTV dose.
Conclusions: The SFO plans achieved significant sparing of normal tissue compared
with theVMATplans formidesophageal cancer. The target dose coverage in the SIB pro-
ton plans was less robust to random setup errors and might be unacceptable for certain
patients. Robust optimization to ensure adequate target coverage of SIB proton plans
might be beneficial. 2016 The Authors. Published by Elsevier Inc. This is an open ac-
cess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Radiation therapy (RT) is an important component in the
management of esophageal cancer, for both preoperative
and definitive treatment, although the 5-year survival rates
in the United Kingdom have been only 12% (1). A meta-
analysis of preoperative chemoradiation therapy suggested
a radiation doseeresponse relationship for improved path-
ologic remission (2) and has provoked interest in RT dose
escalation to improve outcomes (3-5).
Advanced RT techniques such as intensity modulated
RT (IMRT) (3, 4) and volumetric modulated arc therapy
(VMAT) (6) offer opportunities for increasing the dose to
the tumor, although normal tissue sparing for some patients
might be limited by the anatomy (5). Proton therapy is
thought to improve sparing of normal tissues. Preliminary
clinical outcomes with passive scattering proton therapy
(PSPT) suggest that 50.4 Gy (relative biological effective-
ness (RBE)) can be safely delivered with concurrent
chemotherapy (7, 8). Also, the results of a planning study
have suggested that using 2 or 3 proton beams with single-
field optimization (SFO) spot scanning proton therapy for
esophageal cancer could improve lung and heart sparing
compared with photon RT (9).
Nonetheless, planning studies to compare x-ray and
proton techniques and to select the most suitable technique
for each patient have been hampered by the nonequivalence
of several aspects of treatment planning and delivery. A fair
comparison should compare similarly advanced delivery
techniques from current clinical practice and should also
assess the robustness of each technique. Therefore, we
chose to compare SFO proton plans and VMAT plans (10,
11). SFO plans using pencil beam scanning have been
shown to generate a more robust target dose distribution for
brain and spine, prostate, and head and neck tumors than
multifield-optimized intensity modulated proton therapy
plans, when the dose distributions are obtained without
robust optimization (12, 13).
The principal factor affecting plan robustness is setup
error due to interfraction variations in patient position.
Daily cone beam computed tomography (CT) image guid-
ance is routinely used for x-ray RT, and although on-line
volumetric image guidance for proton therapy is not yet
feasible in clinical practice, daily beam’s eye view images
would allow patient positioning with bony anatomy orfiducial markers as a reference (14). Additional uncertainty
is present for proton beams, arising from the uncertainty in
CT number and conversion to proton stopping power,
which can modify the proton range in the patient (15).
The present study therefore examined the robustness of
the VMAT and SFO dose distributions for a range of pa-
tients with midesophageal cancer, assessing the effect of
setup error and additional proton range uncertainty on the
doseevolume metrics for the target and normal tissues.
Methods and Materials
A subset of 21 patients with midthoracic esophageal cancer
was selected from the SCOPE1 clinical trial (ISRCTN
47718479) database (in which the mean planning target
volume (PTV) for the entire cohort was 334 cm3). The 21
patients selected as representative had a PTV range of 140
to 591 cm3 and a mean PTV of 327 cm3. The SCOPE
protocol standard margins (16) were reapplied to the trial-
derived gross tumor volumes (GTVs). The GTV was
increased manually 2 cm superoinferiorly along the
esophageal axis, with an additional 1 cm radial margin to
create the clinical target volume (CTV50Gy). An additional
1 cm margin was applied to create the planning target
volume (PTV50Gy), which was prescribed a dose of 2 Gy/
fraction for 25 fractions. The boost volume CTV62.5Gy was
considered identical to the GTV, with PTV62.5Gy created by
adding an isotropic 0.5 cm margin. This was prescribed a
simultaneous integrated boost dose of 2.5 Gy/fraction
(Fig. 1). A 0.5 cm margin is the minimum value calculated
from random and systematic errors recorded when portal
imaging of bony anatomy is used for image guidance in
esophageal cancer (17). This margin allows for dose falloff
from 62.5 to 50 Gy and minimizes the volume of tissue
irradiated to >50 Gy. Visual assessment of normal tissue
contours was performed, with data imported into Eclipse,
version 13 (Varian, Palo Alto, CA). Two treatment plans
were then created for each patient: a RapidArc (VMAT)
plan using two 360 arcs of 6 MV and a spot scanning
proton therapy plan (SFO) of 70 to 250 MeV using the 3-
field beam arrangement described by Welsh et al (9) with
single-field optimization (Fig. 2, top row). Both plans were
created in physical dose (Gy; ie, proton RBE fixed at a
constant value of 1.1), and the beams were optimized using
all the constraints listed in Table 1, to achieve the correct
PTV50Gy
CTV50Gy
PTV62.5Gy
GTV
PTV50Gy
CTV50Gy
GTV
a b
Fig. 1. Target volumes and dose prescription for (a)
standard and (b) simultaneous integrated boost plans. Ab-
breviations: CTV Z clinical target volume; GTV Z gross
tumor volume; PTV Z planning target volume.
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imal and distal range margin (range 0.3-0.5 cm) was added
to the PTV50Gy. A PTV62.5Gy median dose (D50%) was used
for plan normalization in the standard plans and showed no
statistically significant difference between the VMAT and
SFO plans. Plan robustness was evaluated for both VMAT
and SFO techniques, using the plan uncertainty tool pro-
vided in Eclipse, version 13. This tool simulates setup and
range errors and recalculates a new dose distribution for
each perturbed plan. Setup errors of x (left to right)
0.5 cm, y (craniocaudal) 0.7 cm, and z (anteroposterior)
0.5 cm were used to generate 6 perturbed plans, repre-
senting the maximum expected interfraction setup error for
VMAT and SFO. These simulations encompassed the
random setup error observed in online image guidance
protocols for esophageal cancer (17). For the proton plans,
the effect of a range error of 3.5% was simulated sepa-
rately (18). Doseevolume metrics for the total dose
(62.5 Gy in 25 fractions) for the nominal VMAT and SFO
plans were compared across all patients using the Wilcoxon
signed rank test in SPSS, version 20.0.0 (IBM Corp,
Armonk, NY), with P<.05 considered significant. For each
patient, the robustness of the VMAT and SFO plans to the
setup errors and the SFO plans to range error were
compared as the dose per fraction.
Results
Nominal plans
The VMAT plans met the dose constraints for 16 of 21
patients. The mean heart dose was exceeded for 3 patients
(patients 7, 11, and 17), and the lung V20Gy limit was not
met for patients 16 and 21. For patient 21 (with the largest
PTV of 590.8 cm3), it was challenging to achieve thedesired PTV50Gy V95% because of the overlap with lung
tissue, although coverage of the CTV50Gy was adequate for
this patient, a D98% of 49.1 Gy (Table E1; available online
at www.redjournal.org). Except for this patient, the
PTV50Gy V95% was 95.8% to 99.9%. For the nominal
VMAT plans across all 21 patients, the mean heart dose was
21.2 Gy (median; range 14.4-29.8), mean lung dose was
13.6 Gy (range 8.4-18.1), lung V20 was 15.6% (range 5.8%-
29.7%), and maximum cord dose (0.1 cm3) was 33.3 Gy
(range 21.5-36.5). The doseevolume metrics for each pa-
tient are provided in Table E1 (available online at www.
redjournal.org).
The nominal SFO plans were able to achieve all dose
constraints for 20 of the 21 patients (Table E1; available
online at www.redjournal.org). The mean heart dose was
just exceeded for patient 11 (25.3 Gy), for whom significant
overlap of the PTV contour with the heart was present. The
target dose coverage was acceptable for all patients, with a
D98% of CTV50Gy >95% of the prescribed dose (PD), a
median CTV50Gy D98% of 48.9 Gy (range 48.3-49.9), and
median GTV D98% of 62.6 Gy (range 62.4-62.9). The
proton plans showed a reduced dose to the normal tissue,
with a mean median lung value of 6.3 Gy (range 2.5-11.4),
lung V20 of 6.6% (range 2.5%-17.1%), and maximum cord
dose of 23.7 Gy (range 0.1-39.3; Table E1; available online
at www.redjournal.org). The higher cord dose of patient 16
allowed greater lung sparing than the VMAT plan. Across
all patients, the SFO mean lung dose was only 50.7%
(Fig. 3) of dose delivered using photons (median; range
23.9%-64.9%), and this result was statistically significant
(Z Z 4.01; P<.001). The SFO mean heart dose was
12.7 Gy (median; range 8.2-25.3), only 59.8% (range
49.1%-84.9%) of the VMAT value (Z Z 4.01; P<.001),
and the low dose to the heart contour was also reduced,
with a significant reduction in the heart V5 for all patients.VMAT and SFO plan robustness
The CTV50Gy coverage in the presence of setup errors was
somewhat reduced (Fig. 4), although for VMAT plans, only
1 patient (patient 16) showed possible dose-per-fraction
deterioration of >5% of the PD. This patient had a large
overlap (2.5%) of lung tissue in the PTV. For SFO, instances
of PD deterioration >5% were observed in 15 of 21 patients.
These were most commonly related to displacements 5 mm
to the left (9 patients) or 7 mm superiorly (9 patients).
Although the absolute minimum SFO dose was always
lower (by 0.6%-7.8% of the PD) for each patient than with
VMAT. The median perturbed SFO dose was only >5%
deterioration level for patient 11, because the proximity of
the target and heart generated sharp dose gradients. Proton
plan range robustness was acceptable: for all patients, the
CTV D98 was 95.0% to 100.4% of the PD. The lowest range
perturbed dose coverage was again for patient 11.
GTV D98 plan robustness is illustrated in Figure 5. The
VMAT and SFO plans were normalized such that the
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Fig. 2. (Top) Example of dose distribution for 1 patient for volumetric arc therapy (VMAT) (Left) and single-field opti-
mization (SFO) (Right) plans. (Middle) The maximum (Max) to minimum (Min) dose difference for the uncertainty plans for
VMAT (Left) and SFO (Right). (Bottom) Doseevolume histogram showing the dose to the target volumes and organs-at-risk
for VMAT (Left) and SFO (Right). Shaded regions indicate the envelope of maximum and minimum dose from the un-
certainty plans.
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VMAT plan GTV dose was slightly greater than the SFO
dose. Setup error in the VMAT plans gave a minimum GTV
D98 value of 99.6% to 102.5% the PD, where the median
dose reduction from the nominal plan was 0.6% of the PD
(range 0.3%-1.6%). The minimum doses were observed for
5-mm displacement right or posteriorly. The setup error in
the SFO plans led to a dose of 0.4% to 2% of the PD. The
largest dose deteriorations occurred in patients 5 and 14,
with 5 mm lateral displacements. Patient 11 (with the sharp
dose gradients around the target to reduce the cardiac dose)again had potentially lower minimum GTV D98 coverage
than that of the other patients. The minimum GTV D98
values with the SFO setup errors were lower than the
VMAT values by 0.3% to 2.2% of the prescribed GTV
dose.
The range errors in the SFO plans resulted in smaller
GTV dose deterioration. The values were within 1% of the
PD for all but 1 patient, with a median deterioration per
fraction of 0.02 Gy (0.8% of the PD).
The reduction in dose to the GTV can be translated to a
reduction in the predicted tumor control probability (TCP)
Table 1 Doseevolume constraints used for analysis of
treatment plans for midesophageal cancer
Doseevolume metric data
PTV50Gy
V95% (47.5 Gy) > 95%
PTV62.5Gy
V95% (59.4 Gy) > 95%
Dmax (0.1 cm
3) <107% (66.9 Gy)
Lung
Mean dose <20 Gy
V20Gy <25%
Heart
Mean dose <25 Gy
V30Gy <45%
CordPRV (5 mm margin)
Dmax (0.1 cm
3) <40 Gy (45 Gy permitted)
Abbreviations: CordPRV Z spinal cord planning risk volume;
Dmax Z maximum dose; PTV Z planning target volume.
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VMAT plans, the TCP was a median of 55.6% (range
54.4%-56.8%); for the SFO technique, the median TCP was
55.1% (range 54.8%-55.3%). When the setup error was
included, the TCP for the VMAT plans decreased by 0.3%
to 1.5% (median 0.8%), and for perturbed SFO plans, the
TCP was decreased by a median of 1.8% (range 1.1%-
2.9%), depending on the patient.
For all VMAT plans, even when setup errors were
considered, the maximum dose (0.1 cm3) to the spinal cord
was always less than the required 1.8 Gy/fraction (equiv-
alent to 45 Gy over the entire treatment course), and also
always less than the recommended 1.6 Gy/fraction (40 Gy
over the treatment course; Figure E1; available online at
www.redjournal.org). For the SFO plans, the spinal cordlung
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Fig. 3. Percentage of doseevolume metric of proton
plans compared with photon plans for organs-at-risk. Me-
dian and interquartile range are shown in the box plot, with
the maximum and minimum values shown as error bars
limits. Abbreviations: SFO Z single-field optimization;
VMAT Z volumetric arc therapy.dose was less than the 1.6-Gy dose per fraction limit for all
nominal plans and for all but 1 patient for all the perturbed
plans. However, patient 16, with a nominal plan spinal cord
dose of 1.57 Gy, showed a possible spinal cord dose
maximum of 1.8 Gy when the setup error was 7 mm
anterior. If this setup error were reproduced at every frac-
tion across the entire treatment course, the resultant dose
would be 45.1 Gy.
The doses to lung and heart delivered with setup un-
certainties were virtually unchanged for all patients (ie, the
same number of patients undergoing VMAT would still not
meet the mean heart dose constraint [patients 7, 11, and 17]
or lung V20Gy limit [patients 16 and 21]). The lung and
heart doseevolume parameters also showed no clinically
significant change for the SFO plans with setup error
uncertainties.Discussion
Our comparison of RT techniques for midesophageal can-
cer indicated that SFO offers improved cardiopulmonary
sparing and equivalent target coverage compared with
VMAT. Previous studies have indicated that arc therapy and
fixed-field IMRT produce esophageal cancer treatment
plans of similar quality (19, 20). The SFO plans signifi-
cantly reduce the dose to normal tissues, with a median
50% decrease in the mean dose to lung tissue, leading to an
expected reduced risk of radiation pneumonitis in these
patients. These findings suggest that SFO plans would be
favorable for all patients, in particular, for those patients in
whom dose escalation with photons is not possible using
the current dose constraints. The mean dose to the whole
heart was also reduced, with an absolute reduction per
patient of 1.9 to 18.7 Gy. Data from a retrospective analysis
of breast cancer survivors suggested a 7% reduction in the
risk of ischemic heart disease for every 1-Gy decrease in
the mean heart dose (21). Also, a significant reduction
occurred with SFO in the heart V5, which was identified as
a dosimetric risk factor in the recent Radiation Therapy
Oncology Group 0617 trial (22). However, the volume of
heart receiving a greater dose (range V40Gy-V60Gy) was
similar with both techniques, indicating that in cases in
which patient anatomy causes close proximity or overlap of
organs-at-risk (OARs) with the target volumes, proton
therapy will not spare these regions any better than will
advanced photon therapy. A recent study of 3-dimensional
conformal RT for esophageal cancer suggested that ven-
tricular segments encompassed by the 45-Gy isodose were
associated with an increased risk of myocardial ischemia
(23). This underlines the need for a correlation of cardiac
toxicity with the doseevolume parameters for heart sub-
structures. Knowledge of the safe dose thresholds for car-
diac structures will allow for better optimization and
comparison of RT plans in the future.
Plan robustness was compared by simulating random
setup errors, with a systematic 3.5% range error for the
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Fig. 4. Clinical target volume (CTV) D98 dose per fraction for each patient for the nominal plans (circles), with perturbed
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D98 coverage was acceptable for VMAT and for SFO when
a 3.5% range error was taken into account. Random setup
error in SFO plans causes a reduction in the dose to the
CTV and GTV, for which the magnitude of the dose dete-
rioration is highly dependent on patient anatomy and the
direction of the displacement. The errors we simulated
were unlikely to be reproduced at every fraction during the
treatment course and can be considered as overly pessi-
mistic; some findings have indicated that dose differences
are washed out if the treatment course is sufficiently frac-
tionated (24). However, for some patients, strategies to
ensure sufficient robustness of the target dose with proton
plans would be necessary. This could include optimizing
the beam angles for OAR sparing and target robustness for
each patient or the use of field-specific margins (25). Large
systematic setup errors or range errors >3.5% could reduce
the apparent robustness of the SFO planning approach we
used, and alternative strategies would be required.
Robustness can also be included in the optimization of
spot-scanning proton beams (26), although for several of
the patients in the present study, the close proximity of
OARs and target volumes meant that robust optimization of
the dose distribution would likely be challenging. A clinical
decision regarding any modification of the target volume
margins or OAR sparing would then be required on a
patient-by-patient basis.
Patient intrafraction motion owing to respiration could
also affect the comparison of the delivered and planned
dose distribution for both techniques. Respiration modifies
the tumor position and the water-equivalent thickness
(WET) of the beam path during the breathing cycle.
Because no 4-dimensional (4D)-CT images were available
for the patients in the SCOPE database, we measured the
WET on a 4D-CT scan of a typical patient with esophageal
cancer from our clinic, which showed WET changes of
<8 mm along the beam axis crossing the diaphragmatic
region. Analysis of the WET variation to select the proton
beam angle (using a 4D-CT data set) has been suggested by
Chang et al (27) to produce robust SFO plans for thoracic
tumors. A planning study using 4D-CT data from lung
cancer patients and comparing passive scattering proton
therapy (PSPT) and IMRT showed that the dosimetric
differences for PSPT were no worse those than for IMRT
(28). A similarly rigorous comparison for spot scanning
would require detailed knowledge of the time-dependent
spot delivery and the interplay with the patient’s respira-
tory cycle. In this context, rescanning methods can
conserve target coverage for lung tumors, even for tumor
motion of 12 mm (29). More significant interfractional
dosimetric changes might occur with changes in the
baseline respiration amplitude or with changes in gastro-
intestinal organ filling, which would require careful image-
guided verification of the patient anatomy and adaptive
replanning during the treatment course.
Inaccuracies in the dose calculation algorithm (in
particular, in the presence of heterogeneities) could alterthe predicted dose distribution (30-32). For our study, the
maximum heart dose or dose fall-off around the PTV might
have been underestimated; however, the GTV coverage and
mean lung dose should have been sufficiently accurate.
Greater accuracy for dose calculations, in particular for
thoracic tumor sites, can be achieved using Monte Carlo
and should be introduced for routine treatment planning for
both photons and protons.
We compared the physical dose distributions; however,
the RBE varies with tissue type and along the path of the
proton beam. The net effect might be an underestimation of
the RBE (and biological dose), which will be small in the
proximal region but can be large in the distal end of the
beam, and could significantly underestimate the hot spots in
the normal tissues surrounding the tumor (33). For our plan
comparison, although the biological lung dose might have
been slightly greater than predicted in the proton plans, the
advantage in lung sparing was still very clear. In contrast,
the dose to heart tissue close to the target could have been
underestimated in the proton plans.Conclusions
SFO plans achieve significant sparing of lung tissue for all
patients with midesophageal cancer compared with VMAT.
Further understanding of the mechanism relating the dose
to heart toxicity is required, although tumors located
adjacent to the heart will always pose a planning challenge,
irrespective of the RT modality. The proton plan dose
coverage of CTV50Gy and GTV was less robust to random
setup errors than were the photon plans, although this was
highly patient dependent and can be offset by the potential
for OAR sparing. More advanced optimization strategies to
ensure adequate target coverage of simultaneous integrated
boost proton plans might be required to compensate for
large systematic setup errors or range errors >3.5%.References
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